Hepatitis C virus (HCV) infection is strongly associated with the development of hepatocellular carcinoma (HCC), particularly in patients without a history of hepatitis B virus (HBV) infection. A study analyzed sera from 253 HCC patients in Japan and found that 61.7% (group I) and 18.2% (group II) had no evidence of HBV infection, while 20.2% (group III) were chronic HBV carriers. HCV antibody prevalence was significantly higher in groups I and II (68.6% and 58.7%) compared to group III (3.9%) and non-HCC cancer patients (10.1%). This suggests a strong link between HCV infection and HCC, especially in patients not attributable to HBV. The study also found that HCV is a major cause of post-transfusion non-A, non-B hepatitis (NANBH) and a significant proportion of sporadic cases. HCV antibody prevalence was higher in HCC patients with no HBV markers, and in those with a history of heavy alcohol consumption. The study indicates that HCV may be transmitted through an unknown route, and that HCV infection is a significant risk factor for HCC, with an estimated 53.7% of HCC cases in the study having a history of previous HCV infection. The study also found that HCV is involved in the development of HCC, as evidenced by the detection of the HCV genome in cirrhotic liver tissues. The study concludes that HCV is a major cause of HCC, and that the actual incidence of HCV in HCC patients is likely higher than previously reported.Hepatitis C virus (HCV) infection is strongly associated with the development of hepatocellular carcinoma (HCC), particularly in patients without a history of hepatitis B virus (HBV) infection. A study analyzed sera from 253 HCC patients in Japan and found that 61.7% (group I) and 18.2% (group II) had no evidence of HBV infection, while 20.2% (group III) were chronic HBV carriers. HCV antibody prevalence was significantly higher in groups I and II (68.6% and 58.7%) compared to group III (3.9%) and non-HCC cancer patients (10.1%). This suggests a strong link between HCV infection and HCC, especially in patients not attributable to HBV. The study also found that HCV is a major cause of post-transfusion non-A, non-B hepatitis (NANBH) and a significant proportion of sporadic cases. HCV antibody prevalence was higher in HCC patients with no HBV markers, and in those with a history of heavy alcohol consumption. The study indicates that HCV may be transmitted through an unknown route, and that HCV infection is a significant risk factor for HCC, with an estimated 53.7% of HCC cases in the study having a history of previous HCV infection. The study also found that HCV is involved in the development of HCC, as evidenced by the detection of the HCV genome in cirrhotic liver tissues. The study concludes that HCV is a major cause of HCC, and that the actual incidence of HCV in HCC patients is likely higher than previously reported.